• Long-term Safety of GnRHa Affirmed in Premenopausal Women Undergoing Chemo for Breast Cancer

    1 month ago - By Medscape

    In premenopausal women with early breast cancer, use of a gonadotropin-releasing hormone agonist during chemotherapy did not increase the risk of cancer recurrence for up to 12 years, according to the PROMISE-GIM6 trial.
    Reuters Health Information
    Read more ...

     

  • Pyrotinib plus chemotherapy may benefit patients with pretreated HER2-positive breast cancer

    Pyrotinib plus chemotherapy may benefit patients with pretreated HER2-positive breast cancer

    1 month ago - By Healio

    Pyrotinib plus capecitabine prolonged OS and PFS compared with lapatinib-capecitabine among patients with pretreated HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.
    The combination also exhibited a manageable safety profile, researchers involved with the randomized phase 3 PHOEBE trial reported.
    “Phase 1 studies preliminarily demonstrated the safety and anti-tumor activity of pyrotinib as a pan-HER-receptor in heavily pretreated HER2-positive metastatic breast cancer,” Binghe Xu, MD,
    Read more ...

     

  • Imaging mass cytometry can ‘aid precision immunology' in cancer research

    Imaging mass cytometry can ‘aid precision immunology' in cancer research

    1 month ago - By Healio

    Imaging mass cytometry appeared feasible and allowed for a more comprehensive overview of triple-negative breast cancer heterogeneity at a single-cell level, according to study results presented at San Antonio Breast Cancer Symposium.
    The next-generation technology also provided insights into the value of adding the anti-PD-L1 monoclonal antibody atezolizumab to neoadjuvant chemotherapy for patients with early high-risk and locally advanced triple-negative breast cancer, results showed.
    “We are experiencing a revolution in the technologies available for
    Read more ...

     

  • Palbociclib regimen fails to extend invasive DFS in early breast cancer

    Palbociclib regimen fails to extend invasive DFS in early breast cancer

    1 month ago - By Healio

    The addition of palbociclib to adjuvant endocrine therapy did not extend invasive DFS for patients with early hormone receptor-positive, HER2-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.
    “The benefits previously observed in the metastatic setting with palbociclib did not translate into the earlier adjuvant setting,” researcher Michael Gnant, MD, FACS, director and chairman of the department of surgery at the Comprehensive Cancer Center of Medical University of Vienna, said during a presentation. “Multiple potential
    Read more ...